View Author
Gerrits, C.J.H.
( C.J.H. Gerrits)
topotecan patient study administration cancer topoisomerase phase course schedule toxicity chapter tumor diarrhea inhibitor level camptothecin topoisomerase i inhibitors callcer phase ii study infusion grade treatment phase i pharmacokinetic 21 days lactone effect topoisomerase i exposure topoisomerase i inhibitor topotecan lactone b.i.d phase i study abstr dose level verweij j ollcol range gi 147211 table phase ii trial activity bioavailability antitumor response xenograft clill verweij trial pharmacologic study 1.2 decrease thrombocytopenia colorectal cancer myelosuppression 3 weeks duration dna topoisomerase i plasma result correlation 1996. percentage colorectal 5 days therapy dose levels concentration liu lf von hoff granulocytopenia 0.5 phase ii studies relationship toxicitie phase i trial schellens jhm neutropenia x 5 administration efficacy
2 Most Recent Publications
|
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
(Article)
Gerrits, C.J.H. Hudson, I. Loos, W.J. Beurden, V. van Verweij, J. Von Hoff, D.D. Schellens, J.H. Burris, H. Eckardt, J.R. Planting, A.S.Th. Burg, M.E.L. van der Rodriguez, G.I. |
1999-01-01
|
|
Prolonged tumor exposure to topoisomerase I inhibitor
(Doctoral Thesis)
Gerrits, C.J.H. |
1997-09-24
|
